Open an account

Takeda Pharmaceutical

TKPHF · TOKYO

$39.93+$0.93 (+2.38%)TodayMarket closed ·
Prev close $39.00

About TKPHF

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

Employees
47,455
Headquarters
Chuo-Ku, Tokyo-To
Listed
May 16, 1949
Sector
Health Care
Industry
Pharmaceuticals
Website
takeda.com

TKPHF key statistics

Market cap
9.97T
Price-earnings ratio
0.00
Dividend yield
3.18%
Average volume
11.68K
Volume
1.83K
Open price
$37.55
High today
$40.00
Low today
$37.55
52 Week high
$39.20
52 Week low
$26.33

Takeda Pharmaceutical (TKPHF) at a glance

Takeda Pharmaceutical (TKPHF) last traded at $39.93, with a market cap of 9.97T, a price-to-earnings ratio of 0.00 and a dividend yield of 3.18%.

Today the stock has traded between $37.55 and $40.00. The current price is 6.3% above the day's low and 0.2% below its high.

Volume so far is 1.83K shares, below the average of 11.68K shares a day.

Over the past year Takeda Pharmaceutical has ranged from $26.33 to $39.20, and now sits 106% of the way up that range.

Takeda Pharmaceutical met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q1 FY27 it reported $70.54 per share against an estimate of $54.92.

TKPHF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 53.9% on average.

  1. Q2 FY25: reported $58.14 per share against an estimate of $33.13
  2. Q3 FY25: reported $14.86 per share against an estimate of $25.44
  3. Q4 FY25: reported -$65.35 per share against an estimate of -$55.79
  4. Q1 FY26: reported $79.40 per share against an estimate of $57.15
  5. Q2 FY26: reported -$7.48 per share against an estimate of $34.14
  6. Q3 FY26: reported $65.65 per share against an estimate of $34.44
  7. Q4 FY26: reported -$15.56 per share against an estimate of -$24.26
  8. Q1 FY27: reported $70.54 per share against an estimate of $54.92

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.